Old Web
English
Sign In
Acemap
>
authorDetail
>
Lei Xu
Lei Xu
Bayer HealthCare Pharmaceuticals
Internal medicine
Medicine
Placebo
Regorafenib
Progression-free survival
4
Papers
69
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The effect of gastrectomy on regorafenib exposure and progression free survival in patients with advanced gastrointestinal stromal tumors
2019
British Journal of Clinical Pharmacology
Floor J.E. Lubberman
Winette T. A. van der Graaf
Lei Xu
Adriaan Cleton
George D. Demetri
Hans Gelderblom
Nielka P. van Erp
Show All
Source
Cite
Save
Citations (3)
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial
2017
Clinical Genitourinary Cancer
Nicholas J. Vogelzang
Robert Coleman
Jeff M. Michalski
Sten Nilsson
Joe M. O’Sullivan
Chris Parker
Anders Widmark
Marcus Thuresson
Lei Xu
Joseph Germino
Oliver Sartor
Show All
Source
Cite
Save
Citations (60)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.
2015
Journal of Clinical Oncology
Axel Grothey
Alfredo Falcone
Yves Humblet
Olivier Bouché
Laurent Mineur
Antoine Adenis
Josep Tabernero
Takayuki Yoshino
Heinz-Josef Lenz
Richard M. Goldberg
Lei Xu
Andrea Wagner
Eric Van Cutsem
Show All
Source
Cite
Save
Citations (3)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.
2015
Journal of Clinical Oncology
Axel Grothey
Alfredo Falcone
Yves Humblet
Olivier Bouché
Laurent Mineur
Antoine Adenis
Josep Tabernero
Takayuki Yoshino
Heinz-Josef Lenz
Richard M. Goldberg
Lei Xu
Andrea Wagner
Eric Van Cutsem
Show All
Source
Cite
Save
Citations (3)
1